Zacks Research Comments on Kodiak Sciences Q1 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities research analysts at Zacks Research issued their Q1 2027 earnings per share estimates for shares of Kodiak Sciences in a research report issued on Wednesday, April 16th. Zacks Research analyst R. Department anticipates that the company will earn ($0.91) per share for the quarter. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. Zacks Research also issued estimates for Kodiak Sciences’ FY2027 earnings at ($3.49) EPS.

Separately, HC Wainwright reissued a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a research report on Monday, March 31st.

Kodiak Sciences Trading Up 20.5 %

Shares of Kodiak Sciences stock opened at $2.84 on Friday. The company has a fifty day simple moving average of $3.40 and a 200-day simple moving average of $5.38. The stock has a market cap of $150.02 million, a price-to-earnings ratio of -0.78 and a beta of 2.40. Kodiak Sciences has a 12-month low of $1.92 and a 12-month high of $11.60.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.06.

Institutional Investors Weigh In On Kodiak Sciences

Several large investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Kodiak Sciences by 10,982.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,268,509 shares of the company’s stock worth $12,622,000 after buying an additional 1,257,063 shares during the last quarter. TCG Crossover Management LLC grew its stake in shares of Kodiak Sciences by 13.6% in the 4th quarter. TCG Crossover Management LLC now owns 1,145,538 shares of the company’s stock valued at $11,398,000 after purchasing an additional 137,380 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Kodiak Sciences in the fourth quarter valued at approximately $11,338,000. Silverarc Capital Management LLC raised its stake in shares of Kodiak Sciences by 100.0% during the fourth quarter. Silverarc Capital Management LLC now owns 1,000,000 shares of the company’s stock worth $9,950,000 after purchasing an additional 500,000 shares during the last quarter. Finally, Boxer Capital Management LLC acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth $9,950,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.